

Jian Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724094/publications.pdf>

Version: 2024-02-01

65
papers

2,048
citations

279487

23
h-index

233125

45
g-index

67
all docs

67
docs citations

67
times ranked

3425
citing authors

#	ARTICLE	IF	CITATIONS
1	Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13253-13257.	3.3	342
2	Enhanced Multiple Anchoring and Catalytic Conversion of Polysulfides by Amorphous MoS ₃ Nanoboxes for High-Performance Li-ion Batteries. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 13071-13078.	7.2	186
3	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 546-554.	0.6	162
4	Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. <i>Journal of Clinical Investigation</i> , 2015, 126, 585-598.	3.9	149
5	Phase I Trial: Cirtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. <i>Cell Stem Cell</i> , 2018, 22, 951-959.e3.	5.2	120
6	Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2016, 5, 1088-1093.	3.9	113
7	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	0.6	102
8	Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1370-1377.	3.3	101
9	Composition-adjustable Ag ⁶⁴ Au substitutional alloy microcages enabling tunable plasmon resonance for ultrasensitive SERS. <i>Chemical Science</i> , 2018, 9, 4009-4015.	3.7	70
10	Cirtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. <i>Leukemia</i> , 2017, 31, 1333-1339.	3.3	66
11	Non-intrusive reduced-order modeling for fluid problems: A brief review. <i>Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering</i> , 2019, 233, 5896-5912.	0.7	63
12	Identification of the gene transcription and apoptosis mediated by TGF β 2 β mad2/3 β mad4 signaling. <i>Journal of Cellular Physiology</i> , 2008, 215, 422-433.	2.0	51
13	Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2017, 31, 2615-2622.	3.3	49
14	Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. <i>Biotechnology Letters</i> , 2008, 30, 2045-2052.	1.1	41
15	Cirtuzumab blocks Wnt5a/ROR1 stimulation of NF- κ B to repress autocrine STAT3 activation in chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1084-1094.	0.6	38
16	Wnt5a induces ROR1 to associate with 14-3-3 η for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2017, 31, 2608-2614.	3.3	37
17	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 170-178.	0.6	36
18	Identification of activity-dependent gene expression profiles reveals specific subsets of genes induced by different routes of Ca ²⁺ entry in cultured rat cortical neurons. <i>Journal of Cellular Physiology</i> , 2007, 212, 126-136.	2.0	33

#	ARTICLE	IF	CITATIONS
19	Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. <i>Biotechnology Letters</i> , 2009, 31, 487-494.	1.1	29
20	Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2019, 33, 653-661.	3.3	28
21	Structure-Activity Studies of Antitumor Agent Irofulven (Hydroxymethylacylfulvene) and Analogues. <i>Journal of Organic Chemistry</i> , 2001, 66, 6158-6163.	1.7	26
22	Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by Coxsackievirus A6. <i>Infection, Genetics and Evolution</i> , 2020, 77, 104054.	1.0	25
23	Morphological and structural engineering in amorphous Cu ₂ MoS ₄ nanocages for remarkable electrocatalytic hydrogen evolution. <i>Science China Materials</i> , 2019, 62, 1275-1284.	3.5	23
24	Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 24731-24736.	0.8	19
25	Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961). <i>Blood</i> , 2015, 126, 1741-1741.	0.6	13
26	A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination. <i>Medicine in Novel Technology and Devices</i> , 2021, 11, 100084.	0.9	12
27	Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. <i>Pharmacological Research</i> , 2020, 151, 104512.	3.1	10
28	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	9
29	Practical aspects of a multigrid discontinuous Galerkin solver for steady and unsteady RANS simulations. <i>International Journal for Numerical Methods in Fluids</i> , 2015, 78, 670-690.	0.9	8
30	Amorphous Mn ₃ O ₄ Nanocages with High Efficiency Charge Transfer for Enhancing Electro-Optic Properties of Liquid Crystals. <i>Small</i> , 2019, 15, e1805475.	5.2	8
31	Data-driven reduced order modeling for parametrized time-dependent flow problems. <i>Physics of Fluids</i> , 2022, 34, .	1.6	8
32	On the use of the discontinuous Galerkin method for numerical simulation of two-dimensional compressible turbulence with shocks. <i>Science China: Physics, Mechanics and Astronomy</i> , 2014, 57, 1758-1770.	2.0	7
33	Enhanced Multiple Anchoring and Catalytic Conversion of Polysulfides by Amorphous MoS ₃ Nanoboxes for High Performance Li-ES Batteries. <i>Angewandte Chemie</i> , 2020, 132, 13171-13178.	1.6	7
34	Hermite WENO-based limiters for high order discontinuous Galerkin method on unstructured grids. <i>Acta Mechanica Sinica/Lixue Xuebao</i> , 2012, 28, 241-252.	1.5	4
35	A new high-accuracy scheme for compressible turbulent flows. <i>International Journal of Computational Fluid Dynamics</i> , 2017, 31, 362-378.	0.5	4
36	Revisit of dilation-based shock capturing for discontinuous Galerkin methods. <i>Applied Mathematics and Mechanics (English Edition)</i> , 2018, 39, 379-394.	1.9	4

#	ARTICLE	IF	CITATIONS
37	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 732.	1.1	4
38	Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1. <i>Blood</i> , 2011, 118, 984-984.	0.6	4
39	Implicit high-order discontinuous Galerkin method with HWENO type limiters for steady viscous flow simulations. <i>Acta Mechanica Sinica/Lixue Xuebao</i> , 2013, 29, 526-533.	1.5	3
40	Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	3
41	Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. <i>Microbial Cell Factories</i> , 2021, 20, 67.	1.9	3
42	Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab. <i>Blood</i> , 2017, 130, 829-829.	0.6	3
43	Programmed deathâ€ligand 1 expression on CD22â€specific chimeric antigen receptorâ€modified T cells weakens antitumor potential. <i>MedComm</i> , 2022, 3, .	3.1	3
44	High-order discontinuous Galerkin solver on hybrid anisotropic meshes for laminar and turbulent simulations. <i>Applied Mathematics and Mechanics (English Edition)</i> , 2014, 35, 799-812.	1.9	2
45	Designing Several Types of Oscillation-Less and High-Resolution Hybrid Schemes on Block-Structured Grids. <i>Communications in Computational Physics</i> , 2017, 21, 1376-1407.	0.7	2
46	Abstract 950: Selective cytotoxicity of A6 peptide against ZAP-70 expressing CLL B-cells. , 2014, , .		2
47	Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53. <i>Blood</i> , 2011, 118, 1786-1786.	0.6	2
48	Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 301-301.	0.6	2
49	Assessment of shock capturing schemes for discontinuous Galerkin method. <i>Applied Mathematics and Mechanics (English Edition)</i> , 2014, 35, 1361-1374.	1.9	1
50	A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S44.	0.2	1
51	Suitability of artificial viscosity discontinuous Galerkin method for compressible turbulence. <i>Science China Technological Sciences</i> , 2017, 60, 1032-1049.	2.0	1
52	High accuracy schemes for compressible turbulence simulations. , 2017, , .		1
53	Electroporation of CRISPR-Cas9 into Malignant B Cells for Loss-of-Function Studies of Target Gene Via Knockout. <i>Methods in Molecular Biology</i> , 2020, 2050, 85-90.	0.4	1
54	Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation. <i>Blood</i> , 2012, 120, 3872-3872.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice. Blood, 2013, 122, 4174-4174.	0.6	1
56	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1713-1713.	0.6	1
57	Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2034-2034.	0.6	1
58	Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3224-3224.	0.6	1
59	Wnt5a Induces Association of ROR1 with 14-3-3 σ to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 349-349.	0.6	1
60	Wnt5a Induces Association of ROR1 with Ca ²⁺ /Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 1846-1846.	0.6	1
61	Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1. Blood, 2013, 122, 2873-2873.	0.6	0
62	Abstract 975: MicroRNA-155 In chronic lymphocytic leukemia influences B-cell receptor signaling. , 2014, , .		0
63	Abstract 1193: Treatment of breast cancer xenografts with paclitaxel enriches for cancer stem cells that can be targeted by a ROR1-specific antibody. , 2016, , .		0
64	Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 4415-4415.	0.6	0
65	FLT3 Ligand-DM1 Conjugate Selectively Targets Acute Myeloid Leukemia Cells with FLT3 Expression. Blood, 2020, 136, 30-31.	0.6	0